AllSci News
Celldex’s barzolvolimab scores pivotal CSU wins after recent setbacks
Celldex Therapeutics (Nasdaq: CLDX) reported positive Phase III results for barzolvolimab in chronic spontaneous urticaria (CSU), with both pivotal EMBARQ...
Viking reports positive monthly and every-other-week VK2735 maintenance data
Subcutaneous VK2735, Viking Therapeutics’ (Nasdaq: VKTX) dual GLP-1/GIP receptor agonist, maintained most of the weight loss achieved during weekly...
Adagene advancing HER2 bispecific TCE into clinic in China
China's National Medical Products Administration (NMPA) has cleared an investigational new drug application for ADG138, a HER2×CD3 bispecific T-cell engager...
Iambic files for IPO after string of Big Pharma AI partnerships
San Diego-based Iambic Therapeutics, an AI-driven oncology drug discovery company that has assembled a roster of Big Pharma partnerships worth up to USD 1.7...
Lexeo expands Friedreich ataxia platform with USD 21.3m Mantle acquisition and CNS collaborations
New York-based Lexeo Therapeutics (Nasdaq: LXEO) has agreed to acquire Mantle Therapeutics, a private clinical-stage company developing oral and biologic...
FDA modernizes drug regulations to formalize support for NAMs
A direct final rule published by the FDA on September 22, 2026 replaces "animal test" and "animal study" — along with "preclinical" and "in vitro" — with...
Boehringer, Envisagenics ink up to USD 1b RNA splicing oncology collaboration
New York-based Envisagenics has entered a multi-year research collaboration and option agreement with Boehringer Ingelheim to identify and validate...
Amgen’s dazodalibep meets Phase III endpoint in systemic Sjögren’s disease
Amgen's (Nasdaq: AMGN) dazodalibep, a CD40 ligand (CD40L) antagonist fusion protein, met its primary endpoint in a Phase III trial of systemic Sjögren's...
Novartis adds China-origin RLT asset through BoomRay licensing deal
Novartis (NYSE: NVS) has agreed to exclusively license a preclinical radioligand therapy (RLT) asset from Suzhou, China-based BoomRay Pharmaceuticals Co.,...
Mayo Clinic researchers identify BCL-XL inhibition strategy to reverse PARP inhibitor resistance in ovarian cancer
Researchers at Mayo Clinic have identified a BCL-XL-dependent survival mechanism that contributes to PARP inhibitor resistance in ovarian cancer and shown...
European Commission approves Roche's Susvimo for neovascular age-related macular degeneration.
A refillable eye implant that delivers anti-vascular endothelial growth factor (anti-VEGF) therapy continuously — rather than through repeated intravitreal...
Roche advances enicepatide toward Phase III after positive diabetes trial
Roche's (OTCQX: RHHBY) enicepatide, a once-weekly dual GLP-1/GIP receptor agonist, produced substantial reductions in both blood glucose and body weight in...
Novo’s CagriSema beats lower-dose tirzepatide in diabetes, meets obesity endpoint
Novo Nordisk's cagrilintide and semaglutide combination CagriSema delivered superior weight loss versus a lower dose of tirzepatide in type 2 diabetes and...
MD Anderson secures USD 2.7m NCI grant for four-part anaplastic thyroid cancer program
The University of Texas MD Anderson Cancer Center has received a USD 2.7 million National Cancer Institute P01 Program Project Grant to advance a...
AbbVie's Rinvoq picks up EU nod for polyarticular juvenile idiopathic arthritis in children
Children as young as two years old in Europe now have access to an oral JAK inhibitor option for polyarticular juvenile idiopathic arthritis (pJIA), after...
The AllSci Brief
Free, systematic R&D and deal news. Daily.